Therapeutic area intelligence for Autoimmune Diseases with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 2

Companies

Kite Pharma →

Quell Therapeutics →

Assets

BGB-45035 →

KITE-363 →

QEL-005 →

Recent signals(3)

ClinicalJuly 5, 2026

KITE-363 Phase 1 Study Initiated for Autoimmune Neurologic Diseases

Kite, Gilead Company, is conducting Phase 1 study to evaluate the safety and efficacy of KITE-363 in patients with relapsed/refractory autoimmune neurologic diseases.

ClinicalJuly 1, 2026

Quell Therapeutics Initiates Phase 1/2 Trial for QEL-005 in Autoimmune Diseases

Quell Therapeutics is conducting Phase 1/2 trial of QEL-005, an autologous CAR-T therapy targeting CD19, in patients with dcSSc and D2TRA.

ClinicalJune 20, 2026

First-in-Human Study of BGB-45035 in Healthy Adults and Autoimmune Patients

The first-in-human study of BGB-45035 will assess its safety and pharmacokinetics in healthy participants and adults with autoimmune dermatological diseases.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Autoimmune Diseases →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.